Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ARWR
CUSIPN/A
Phone626-304-3400
Debt
Debt-to-Equity Ratio0.02
Current Ratio10.16
Quick Ratio10.16
Price-To-Earnings
Trailing P/E Ratio-28.21
Forward P/E Ratio-17.92
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.41 million
Price / Sales36.97
Cash FlowN/A
Price / CashN/A
Book Value$1.08 per share
Price / Book12.28
Profitability
EPS (Most Recent Fiscal Year)($0.47)
Net Income$-34,380,000.00
Net Margins-199.55%
Return on Equity-50.05%
Return on Assets-40.83%
Miscellaneous
Employees93
Outstanding Shares87,580,000
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Frequently Asked Questions
What is Arrowhead Pharmaceuticals' stock symbol?
Arrowhead Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARWR."
How were Arrowhead Pharmaceuticals' earnings last quarter?
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) issued its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. The biotechnology company earned $0.65 million during the quarter, compared to analyst estimates of $4.04 million. Arrowhead Pharmaceuticals had a negative return on equity of 50.05% and a negative net margin of 199.55%. View Arrowhead Pharmaceuticals' Earnings History.
When is Arrowhead Pharmaceuticals' next earnings date?
What price target have analysts set for ARWR?
6 Wall Street analysts have issued twelve-month price targets for Arrowhead Pharmaceuticals' stock. Their predictions range from $4.00 to $13.00. On average, they expect Arrowhead Pharmaceuticals' share price to reach $9.4467 in the next year. View Analyst Ratings for Arrowhead Pharmaceuticals.
What are Wall Street analysts saying about Arrowhead Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arrowhead Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $13 PT for the completed enrollment of the Phase 1 trial of ARO-AAT for the treatment of Alpha-1 liver disease. We are encouraged by the impressive execution and rapid enrollment of 44 patients in approximately three months." (6/18/2018)
- 2. Chardan Capital analysts commented, "We believe that Arrowhead is positioned to achieve a number of significant milestones in 2018. The Company spent most of 2017 quietly regrouping following its announcement in November 2016 that it was discontinuing all of its clinical RNAi programs (ARC-520, ARC-521, and ARC-AAT), which use its dynamic polyconjugate (DPC) delivery technology. The decision to discontinue development of these programs was based on the substantial delays that would have occurred in order to further explore the cause of deaths in a non-clinical toxicology study in non-human primates. Arrowhead subsequently reduced its workforce by approximately 30%. In September 2017, the Company unveiled its new proprietary delivery technology they call Targeted RNAi Molecule (TRiM), along with a portfolio of newly named candidates. Arrowhead’s TRiM delivery technology leverages advances in RNA chemistry and targeting, to deliver a payload with increased potency." (2/19/2018)
Who are some of Arrowhead Pharmaceuticals' key competitors?
Some companies that are related to Arrowhead Pharmaceuticals include Ligand Pharmaceuticals (LGND), GW Pharmaceuticals (GWPH), Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Madrigal Pharmaceuticals (MDGL), HUTCHISON CHINA/S (HCM), Amicus Therapeutics (FOLD), Blueprint Medicines (BPMC), Supernus Pharmaceuticals (SUPN), Horizon Pharma (HZNP), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Portola Pharmaceuticals (PTLA) and The Medicines (MDCO).
Who are Arrowhead Pharmaceuticals' key executives?
Arrowhead Pharmaceuticals' management team includes the folowing people:
- Dr. Christopher R. Anzalone, CEO, Pres & Director (Age 49)
- Mr. Kenneth A. Myszkowski, Chief Financial Officer (Age 52)
- Dr. Bruce D. Given, Chief Operating Officer (Age 64)
- Mr. Patrick O'Brien, Gen. Counsel (Age 54)
- Mr. Peter B. Leone MBA, VP of Strategic Bus. Initiatives (Age 61)
Has Arrowhead Pharmaceuticals been receiving favorable news coverage?
Headlines about ARWR stock have been trending somewhat negative on Sunday, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a media sentiment score of -0.02 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 44.30 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
Who are Arrowhead Pharmaceuticals' major shareholders?
Arrowhead Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include OppenheimerFunds Inc. (8.91%), RTW INVESTMENTS, LP (5.02%), BlackRock Inc. (3.92%), Acuta Capital Partners LLC (2.01%), Nexthera Capital LP (1.27%) and Millennium Management LLC (0.93%). Company insiders that own Arrowhead Pharmaceuticals stock include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Institutional Ownership Trends for Arrowhead Pharmaceuticals.
Which institutional investors are selling Arrowhead Pharmaceuticals stock?
ARWR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, A.R.T. Advisors LLC, Alpine Global Management LLC and Barclays PLC. Company insiders that have sold Arrowhead Pharmaceuticals company stock in the last year include Bruce D Given, Christopher Richard Anzalone, Douglas B Given and Kenneth Allen Myszkowski. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
Which institutional investors are buying Arrowhead Pharmaceuticals stock?
ARWR stock was purchased by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, OppenheimerFunds Inc., Nexthera Capital LP, BlackRock Inc., Iguana Healthcare Management LLC, UBS Group AG, Tibra Equities Europe Ltd and GSA Capital Partners LLP. View Insider Buying and Selling for Arrowhead Pharmaceuticals.
How do I buy shares of Arrowhead Pharmaceuticals?
Shares of ARWR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arrowhead Pharmaceuticals' stock price today?
One share of ARWR stock can currently be purchased for approximately $13.26.
How big of a company is Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals has a market capitalization of $1.15 billion and generates $31.41 million in revenue each year. The biotechnology company earns $-34,380,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. Arrowhead Pharmaceuticals employs 93 workers across the globe.
How can I contact Arrowhead Pharmaceuticals?
Arrowhead Pharmaceuticals' mailing address is 225 SOUTH LAKE AVENUE SUITE 1050, PASADENA CA, 91101. The biotechnology company can be reached via phone at 626-304-3400 or via email at [email protected]
MarketBeat Community Rating for Arrowhead Pharmaceuticals (ARWR)
MarketBeat's community ratings are surveys of what our community members think about Arrowhead Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARWR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARWR will underperform the S&P 500 over the long term. You may vote once every thirty days.
